Joshi A, Patil V M, Noronha V, Juvekar S, Deshmukh A, Chatturvedi P, Chaukar D A, Agarwal J P, Ghosh S, Murthy V, D'cruz A, Prabhash K
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Cancer. 2013 Oct-Dec;50(4):349-55. doi: 10.4103/0019-509X.123627.
The objective of the following study is to investigate the efficacy and impact of induction chemotherapy in T4b oral cavity cancers.
It's a retrospective analysis of prospectively collected data of T4b oral cavity cancer patients who were offered induction chemotherapy and then assessed for resectability at the end of 2 cycles of chemotherapy. Post-induction these patients either underwent surgical or non-surgical local intervention depending upon their response. These patients were then followed-up until either recurrence progression or death whichever was later. Statistical analysis was performed by SPSS version 16. Descriptive analysis was performed. Factors affecting achievement of resectability were sought by univariate and multivariate analysis. The impact of surgery on overall survival (OS) was studied using Kaplan Meier survival analysis with the use of log rank test.
A total of 110 patients received chemotherapy. Median age been 41.5 years (range 25-66 years). 21 (20%) of our patient received 3 drug regimen while the rest of our patients received 2 drug regimen. Partial response was achieved in 28 patients, stable disease in 49 patients and progression was noted in 23 patients. Resectability was achieved in 34 (30.9%) of 110 patients. The estimated median OS in patients who underwent surgery was 18.0 months (95% confidence interval [CI]: 13.6-22.46 months) and for those treated with non-surgical treatment was 6.5 months (95% CI: 5.6-7.4 months) (P = 0.0001).
Use of induction chemotherapy is safe and can achieve resectability in 30.9% of our T4b patients. In those patients undergoing resection have much better OS then those who underwent non-surgical local treatment.
以下研究的目的是调查诱导化疗在T4b期口腔癌中的疗效和影响。
这是一项对前瞻性收集的T4b期口腔癌患者数据的回顾性分析,这些患者接受了诱导化疗,并在化疗2周期结束时评估其可切除性。诱导化疗后,这些患者根据反应情况接受手术或非手术局部干预。然后对这些患者进行随访,直至复发、进展或死亡(以较晚者为准)。使用SPSS 16版进行统计分析。进行描述性分析。通过单因素和多因素分析寻找影响可切除性实现的因素。使用Kaplan Meier生存分析和对数秩检验研究手术对总生存期(OS)的影响。
共有110例患者接受化疗。中位年龄为41.5岁(范围25 - 66岁)。21例(20%)患者接受三联药物方案,其余患者接受二联药物方案。28例患者获得部分缓解,49例患者病情稳定,23例患者病情进展。110例患者中有34例(30.9%)实现了可切除性。接受手术的患者估计中位OS为18.0个月(95%置信区间[CI]:13.6 - 22.46个月),接受非手术治疗的患者为6.5个月(95% CI:5.6 - 7.4个月)(P = 0.0001)。
诱导化疗的使用是安全的,并且可以使30.9%的T4b期患者实现可切除性。在接受手术切除的患者中,其总生存期比接受非手术局部治疗的患者要好得多。